About the Company
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland, that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on development and approval of its NVX-CoV2373 vaccine for COVID-19. The COVID-19 vaccine Nuvaxovid was approved in the European Union at the end of 2021, and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen and AstraZeneca.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on NOVAVAX INC
What the Options Market Tells Us About Novavax
In terms of liquidity and interest, the mean open interest for Novavax options trades today is 6075.0 with a total volume of 9,211.00. In the following chart, we are able to follow the development of ...
Novavax Shares Are Trading Higher Thursday: What's Going On?
The new notes carry an initial conversion price of $11.14 per share, a 27.5% premium to Novavax's closing price on August 20, 2025. Following the transaction, which is expected to close on or about ...
Novavax Announces $225M Convertible Senior Notes Issuance
Novavax ( ($NVAX) ) has provided an update. On August 20, 2025, Novavax announced it had entered into agreements to issue $225 million in 4.625% ...
Novavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, expectations were $-0.19. Operator: Good morning, and welcome to Novavax Second ...
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is ... - Nasdaq
Novavax reported revenues of $415.48 million in the last reported quarter, representing a year-over-year change of -2.1%. EPS of $0.99 for the same period compares with $0.58 a year ago.
Novavax Strengthens Position with Vaccine Approval and Sanofi Partnership
Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before ... - Nasdaq
Novavax is expected to post a loss of $0.12 per share for the current quarter, representing a year-over-year change of -112.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -280.8%.
Novavax seeks FDA emergency use authorization for Covid-19 vaccine ...
Gaithersburg’s Novavax Inc. has submitted its long-awaited request for approval in the U.S. for its experimental Covid-19 vaccine, following several months of manufacturing delays and buildup ...
Novavax’s Updated Covid Shot Falls Short of Original
Novavax Inc. shares fell after the company released data showing its current Covid-19 vaccine produced a better immune response than an experimental bivalent shot that targets omicron variants.
Novavax exec says its new COVID shot should work against variants on ...
Novavax Inc's head of research and development on Monday said an updated COVID-19 vaccine the company is already producing is likely to be protective against other fast-growing coronavirus ...
Novavax COVID shot, aimed at vaccine skeptics, overwhelmingly backed by ...
Advisers to the U.S. Food and Drug Administration on Tuesday voted overwhelmingly to recommend that the agency authorize Novavax Inc's COVID-19 vaccine for use in adults, which the drugmaker hopes ...
Similar Companies
Loading the latest forecasts...